Zantac® (Ranitidine) Recall Update

Zantac 150

Independent laboratory testing of products containing ranitidine, including Zantac®, has found dangerous levels of N-nitrososdimethylamine (NDMA), a probable human carcinogen, in them. In fact, it has been uncovered that the amount of NDMA found in Zantac® is 3,171 times greater than the daily intake limit as stated by the FDA.

A History of Alerts and Recalls

From the time that the independent lab testing showed the dangerous amount of NDMA in Zantac® and other products, until now, updates have continued to pour in and ranitidine products have continued to be recalled.

  • September 2019
    • FDA issues a statement alerting the public that NDMA was found in samples of ranitidine.
    • FDA announces voluntary recall of Sandoz ranitidine capsules following the detection of an impurity.
    • FDA issues alert to health care professionals and patients to the voluntary recall of ranitidine medications manufactured by Apotex Corp and labeled by Walgreens, Walmart, and Rite-Aid.
  • October 2019
    • FDA urges manufacturers to conduct independent lab testing of ranitidine products for potential contamination, recommending the use of an LC-HRMS testing protocol.
    • FDA announces voluntary recalls of ranitidine by manufacturers of the following: Perrigo Company plc, Sanofi, Dr. Reddy’s, Lannett Company Inc., and Novitium Pharma.
  • November 2019
    • FDA releases laboratory-testing results for NDMA in ranitidine and released a statement from the director of the FDA’s Center for Drug Evaluation and Research.
    • FDA alerts public of additional voluntary recalls of ranitidine products by the manufacturers Aurobindo Pharma USA and Amneal Pharmaceuticals LLC.
  • December 2019
    • FDA requires additional testing of nizatidine and ranitidine as part of the agency’s ongoing effort to help ensure product safety.
    • FDA alerts the public of Glenmark’s voluntary recall of ranitidine.
  • January 2020
    • FDA alerts the public of Mylan’s voluntary recall of nizatidine as well as Appco Pharma LLC’s recall of ani.

Cancers Linked to Zantac® (Ranitidine) Use

According to studies, the most common types of cancer that can result from ingesting Zantac® (ranitidine) include:

  • Kidney Cancer
  • Liver Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • Bladder Cancer
  • Stomach Cancer
  • Intestinal Cancer
  • Testicular Cancer
  • Esophageal Cancer
  • Colorectal Cancer
  • Uterine Cancer

The Attorneys at Carter Mario Law Firm Can Help

If you or a loved one has taken Zantac® and subsequently suffered adverse effects from the drug, you may be entitled to compensation.

Contact the experienced dangerous drug lawyers at Carter Mario today by calling  (203) 806-9256 or by filling out a free no-obligation consultation form online.

Get Carter! Guaranteed Tough! Guaranteed Fast!